A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

Inclusion Criteria Participants who meet all of the following criteria are eligible for this study: * Participant is greater than or equal to (\>= 7) years old. * Participant with confirmed diagnosis of Fabry disease (by investigator). * Participant never received or has received ERT (agalsidase alfa or agalsidase beta) within 12 weeks at most prior to enrolment. * Participant who will receive ERT with agalsidase alfa in routine clinical practice settings. * For \>= 18 years old, participant should sign the informed consent form (ICF); for 8-17 years old, participant and his (her) parents/ legally authorized representative (LAR) should both sign the ICF; for \< 8 years old, participant will give assent and his (her) parents/legally authorized representative should sign the ICF accordingly. Exclusion Criteria * Participant will be excluded if they have documented New York Heart Association (NYHA) functional Class IV heart failure symptoms (Implantable cardioverter-defibrillator \[ICD\] implanted excluded), third-degree atrioventricular block (ICD implanted excluded), acute myocardial infarction within the last 3 months and severe stroke (NIH Stroke Scale \[NIHSS\] \>= to 21). * Participant has enrolled in Fabry disease interventional clinical trial currently. * Other situations that the investigator considers not suitable for participation in this study.